Literature DB >> 16148347

Editorial: glucocorticoids for Graves' ophthalmopathy: how and when.

Luigi Bartalena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16148347     DOI： 10.1210/jc.2005-1553

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  7 in total

1.  Genetic profiling in Graves' disease: further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy.

Authors:  Xiaoming Yin; Rauf Latif; Rebecca Bahn; Terry F Davies
Journal:  Thyroid       Date:  2012-06-04       Impact factor: 6.568

Review 2.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Radioiodine treatment of hyperthyroidism.

Authors:  Anthony Toft; Thekkepat C Sandeep
Journal:  BMJ       Date:  2007-03-10

Review 4.  Diagnosis and management of Graves disease: a global overview.

Authors:  Luigi Bartalena
Journal:  Nat Rev Endocrinol       Date:  2013-10-15       Impact factor: 43.330

Review 5.  Dose of intravenous steroids and therapy outcome in Graves' orbitopathy.

Authors:  S Zang; K A Ponto; S Pitz; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2011-12       Impact factor: 4.256

Review 6.  Hyperthyroidism.

Authors:  Mala Sharma; Wilbert S Aronow; Laxesh Patel; Kaushang Gandhi; Harit Desai
Journal:  Med Sci Monit       Date:  2011-04

7.  Radioiodine therapy and Graves' disease - Myths and reality.

Authors:  Maria Teresa Plazinska; Nadia Sawicka-Gutaj; Agata Czarnywojtek; Kosma Wolinski; Małgorzata Kobylecka; Maria Karlińska; Karolina Prasek; Małgorzata Zgorzalewicz-Stachowiak; Magdalena Borowska; Paweł Gut; Marek Ruchala; Leszek Krolicki
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.